Key Takeaways
- • David Beckham's health drink startup IM8 secured $1 billion in non-dilutive funding from General Catalyst's Customer Value Fund (CVF), announced July 14, 2026, preserving founder ownership without equity dilution.
- • General Catalyst's CVF structure functions as revenue-based financing rather than traditional venture equity: the fund provides capital and receives repayment of principal plus a capped percentage of revenue generated from financed customer acquisition costs, with no ownership stake.
- • IM8, a Prenetics subsidiary co-founded by CEO Danny Yeung (founder of Prenetics, which went public in 2022), sells subscription-based vitamin drinks formulated with longevity-linked compounds including açai fruit extract and Coenzyme Q10.
- • The $1 billion loan finances up to 70% of IM8's customer acquisition costs; General Catalyst receives a capped share of "reference income" (revenue multiplied by fixed gross-margin assumption), with all surplus revenue reverting to Prenetics post-recovery and cap achievement.
- • This represents the second major CVF deployment at this scale, following Grammarly's $1 billion revenue-based financing in May 2025 prior to its acquisition of Superhuman.
Summary
David Beckham's health drink startup IM8 has closed a $1 billion funding round from General Catalyst's Customer Value Fund (CVF), marking a significant capital deployment for the Prenetics subsidiary focused on longevity-oriented beverage products. The announcement, made on July 14, 2026, demonstrates continued institutional appetite for non-traditional venture financing structures suited to businesses with established revenue predictability.
The CVF structure diverges fundamentally from conventional equity venture capital. Rather than acquiring an ownership stake, General Catalyst provides capital structured as a loan with revenue-based repayment terms. IM8 will repay the principal amount alongside a fixed, capped percentage of revenue generated. Critically, this arrangement avoids equity dilution to existing shareholders and does not grant General Catalyst voting rights or board representation. According to General Catalyst's previous commentary to TechCrunch, this financing model targets startups demonstrating predictable revenue streams and clear capital deployment strategies for accelerating growth.
IM8 was co-founded by Danny Yeung, CEO and self-described high school dropout who previously founded Prenetics, a health company that achieved public listing in 2022. Yeung's connection to David Beckham reportedly originated through a dinner that catalyzed the creation of IM8. The startup operates a subscription-based model selling vitamin drinks formulated with compounds associated with longevity benefits, including açai fruit extract and Coenzyme Q10. Prenetics maintains ownership of IM8 as a subsidiary.
The $1 billion facility is specifically structured to finance up to 70% of IM8's customer acquisition costs. General Catalyst's return mechanism is tied to "reference income," calculated as revenue from those customers multiplied by a fixed gross-margin assumption. Once General Catalyst recovers its full investment and reaches its capped revenue share, all subsequent revenue from financed customers flows to Prenetics. This repayment architecture aligns funder and founder interests around customer lifetime value rather than traditional venture exit events.
The IM8 transaction represents a second major CVF deployment at the $1 billion scale, following Grammarly's $1 billion revenue-based financing in May 2025, which preceded Grammarly's acquisition of Superhuman. The repeated use of CVF at this capital scale suggests General Catalyst's confidence in the model for mature, revenue-generating technology and consumer businesses.
The CVF structure diverges fundamentally from conventional equity venture capital. Rather than acquiring an ownership stake, General Catalyst provides capital structured as a loan with revenue-based repayment terms. IM8 will repay the principal amount alongside a fixed, capped percentage of revenue generated. Critically, this arrangement avoids equity dilution to existing shareholders and does not grant General Catalyst voting rights or board representation. According to General Catalyst's previous commentary to TechCrunch, this financing model targets startups demonstrating predictable revenue streams and clear capital deployment strategies for accelerating growth.
IM8 was co-founded by Danny Yeung, CEO and self-described high school dropout who previously founded Prenetics, a health company that achieved public listing in 2022. Yeung's connection to David Beckham reportedly originated through a dinner that catalyzed the creation of IM8. The startup operates a subscription-based model selling vitamin drinks formulated with compounds associated with longevity benefits, including açai fruit extract and Coenzyme Q10. Prenetics maintains ownership of IM8 as a subsidiary.
The $1 billion facility is specifically structured to finance up to 70% of IM8's customer acquisition costs. General Catalyst's return mechanism is tied to "reference income," calculated as revenue from those customers multiplied by a fixed gross-margin assumption. Once General Catalyst recovers its full investment and reaches its capped revenue share, all subsequent revenue from financed customers flows to Prenetics. This repayment architecture aligns funder and founder interests around customer lifetime value rather than traditional venture exit events.
The IM8 transaction represents a second major CVF deployment at the $1 billion scale, following Grammarly's $1 billion revenue-based financing in May 2025, which preceded Grammarly's acquisition of Superhuman. The repeated use of CVF at this capital scale suggests General Catalyst's confidence in the model for mature, revenue-generating technology and consumer businesses.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.